Quantinno Capital Management LP Has $9.70 Million Stake in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

Quantinno Capital Management LP lifted its stake in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX - Free Report) by 22.2% during the 4th quarter, according to its most recent Form 13F filing with the SEC. The fund owned 24,076 shares of the pharmaceutical company's stock after purchasing an additional 4,381 shares during the period. Quantinno Capital Management LP's holdings in Vertex Pharmaceuticals were worth $9,695,000 as of its most recent filing with the SEC.

Several other large investors have also modified their holdings of VRTX. ABC Arbitrage SA acquired a new stake in shares of Vertex Pharmaceuticals in the fourth quarter valued at approximately $1,510,000. Highview Capital Management LLC DE increased its stake in shares of Vertex Pharmaceuticals by 1.8% during the fourth quarter. Highview Capital Management LLC DE now owns 5,771 shares of the pharmaceutical company's stock valued at $2,324,000 after acquiring an additional 102 shares during the period. Davidson Investment Advisors grew its position in Vertex Pharmaceuticals by 26.0% in the fourth quarter. Davidson Investment Advisors now owns 61,161 shares of the pharmaceutical company's stock worth $24,630,000 after buying an additional 12,631 shares during the last quarter. Jones Financial Companies Lllp grew its position in Vertex Pharmaceuticals by 75.5% in the fourth quarter. Jones Financial Companies Lllp now owns 2,468 shares of the pharmaceutical company's stock worth $994,000 after buying an additional 1,062 shares during the last quarter. Finally, Concord Wealth Partners grew its position in Vertex Pharmaceuticals by 32.6% in the fourth quarter. Concord Wealth Partners now owns 3,508 shares of the pharmaceutical company's stock worth $1,413,000 after buying an additional 862 shares during the last quarter. Institutional investors own 90.96% of the company's stock.

Insider Activity

In other news, EVP Ourania Tatsis sold 244 shares of Vertex Pharmaceuticals stock in a transaction dated Tuesday, February 18th. The shares were sold at an average price of $455.06, for a total transaction of $111,034.64. Following the sale, the executive vice president now directly owns 67,695 shares in the company, valued at approximately $30,805,286.70. The trade was a 0.36% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP David Altshuler sold 3,231 shares of the business's stock in a transaction dated Monday, March 10th. The shares were sold at an average price of $500.00, for a total transaction of $1,615,500.00. Following the completion of the transaction, the executive vice president now owns 26,512 shares in the company, valued at approximately $13,256,000. This trade represents a 10.86% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 4,057 shares of company stock worth $2,000,549. Corporate insiders own 0.20% of the company's stock.

Analysts Set New Price Targets

VRTX has been the subject of a number of recent analyst reports. Morgan Stanley raised their price objective on shares of Vertex Pharmaceuticals from $462.00 to $464.00 and gave the stock an "equal weight" rating in a research note on Tuesday, May 6th. HC Wainwright reaffirmed a "buy" rating and issued a $550.00 price objective on shares of Vertex Pharmaceuticals in a research note on Tuesday, February 11th. Scotiabank decreased their price objective on shares of Vertex Pharmaceuticals from $450.00 to $442.00 and set a "sector perform" rating for the company in a research note on Tuesday, May 6th. Wolfe Research lowered shares of Vertex Pharmaceuticals from an "outperform" rating to a "peer perform" rating in a research note on Wednesday, May 7th. Finally, The Goldman Sachs Group reaffirmed a "buy" rating on shares of Vertex Pharmaceuticals in a research note on Tuesday, May 6th. Thirteen research analysts have rated the stock with a hold rating, sixteen have assigned a buy rating and one has given a strong buy rating to the company's stock. According to MarketBeat, Vertex Pharmaceuticals presently has a consensus rating of "Moderate Buy" and an average target price of $515.04.

Vertex Pharmaceuticals Stock Performance

Shares of NASDAQ:VRTX traded up $2.01 on Monday, hitting $440.66. 1,182,493 shares of the company were exchanged, compared to its average volume of 1,409,127. The company's 50 day moving average price is $482.97 and its two-hundred day moving average price is $464.36. Vertex Pharmaceuticals Incorporated has a one year low of $377.85 and a one year high of $519.88. The company has a debt-to-equity ratio of 0.01, a quick ratio of 2.35 and a current ratio of 2.69. The firm has a market capitalization of $113.16 billion, a price-to-earnings ratio of -200.30, a PEG ratio of 2.11 and a beta of 0.51.

Vertex Pharmaceuticals (NASDAQ:VRTX - Get Free Report) last posted its quarterly earnings data on Monday, May 5th. The pharmaceutical company reported $4.06 earnings per share (EPS) for the quarter, missing the consensus estimate of $4.29 by ($0.23). Vertex Pharmaceuticals had a negative return on equity of 2.02% and a negative net margin of 4.86%. The company had revenue of $2.77 billion for the quarter, compared to the consensus estimate of $2.85 billion. During the same quarter in the previous year, the firm posted $4.76 EPS. The business's revenue for the quarter was up 2.6% compared to the same quarter last year. Research analysts expect that Vertex Pharmaceuticals Incorporated will post 15.63 earnings per share for the current year.

About Vertex Pharmaceuticals

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.